BCL2L1 and neuroblastoma: While Venetoclax could induce therapeutic resistance by up-regulating Bcl-xL and Mcl1 expression in some instances [293], it has shown encouraging results as a single agent for treating acute lymphocytic leukemia (ALL) [294], head and neck squamous cell carcinoma (HNSCC) [295] and neuroblastoma [296, 297] in pre-clinical models.